NextCell Pharma AB (FRA:65G) Land And Improvements : €0.00 Mil (As of Feb. 2025)

View and export this data going back to 2020. Start your Free Trial

What is NextCell Pharma AB Land And Improvements?

NextCell Pharma AB's land and improvements for the quarter that ended in Feb. 2025 was €0.00 Mil.

NextCell Pharma AB Land And Improvements Historical Data

The historical data trend for NextCell Pharma AB's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextCell Pharma AB Land And Improvements Chart

NextCell Pharma AB Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

Land And Improvements

Get a 7-Day Free Trial

NextCell Pharma AB Quarterly Data
	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25
Land And Improvements	Get a 7-Day Free Trial															-	-	-	-	-

NextCell Pharma AB Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

NextCell Pharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCell Pharma AB (FRA:65G) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

NXTCL:Sweden

Address

Karolinska Institutet Science Park, Halsovagen 7, Huddinge, SWE, 14157

Website

http://www.nextcellpharma.com

NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.

NextCell Pharma AB Headlines

No Headlines